60 Degrees Pharmaceuticals (SXTP) announced its entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against the vector-borne bacteria, Borrelia and Bartonella, in cell culture. Together with Babesia, these three pathogens are known as the “3Bs” in the Lyme disease community. “The purpose of this study is to gain a better understanding of these rapidly spreading tick-borne diseases for which there is a growing unmet need for effective, approved treatments,” said Chief Executive Officer of 60 Degrees Pharma, Geoff Dow. “Tafenoquine continues to perform well in babesiosis trials currently underway in several sites. The Tulane University study will help further elucidate tafenoquine’s potential for treating co-infections in babesiosis patients.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals prices 2.6M shares at $1.90 in public offering
- 60 Degrees determines max commercial market size for ARAKODA at $245M annually
- 60 Degrees Pharmaceuticals to submit tafenoquine MUMS designation request to FDA
- Closing Bell Movers: Merit Medical Systems gains after Q2 outlook
- 60 Degrees Pharmaceuticals to sell 2.04M shares of common stock for holders